Details
Stereochemistry | ACHIRAL |
Molecular Formula | C18H19F3N2S |
Molecular Weight | 352.417 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)CCCN1C2=C(SC3=C1C=C(C=C3)C(F)(F)F)C=CC=C2
InChI
InChIKey=XSCGXQMFQXDFCW-UHFFFAOYSA-N
InChI=1S/C18H19F3N2S/c1-22(2)10-5-11-23-14-6-3-4-7-16(14)24-17-9-8-13(12-15(17)23)18(19,20)21/h3-4,6-9,12H,5,10-11H2,1-2H3
Triflupromazine is antipsychotic and an antiemetic drug (sold under the brand names VESPRIN) which used to management of psychoses. However, this drug was discontinued. Triflupromazine binds to the dopamine D1 and dopamine D2 receptors and inhibits their activity. Moreover, binds the muscarinic acetylcholine receptors (M1 and M2).
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P11229 Gene ID: 1128.0 Gene Symbol: CHRM1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/1678146 |
|||
Target ID: P08172 Gene ID: 1129.0 Gene Symbol: CHRM2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/4152054 |
|||
Target ID: CHEMBL2056 |
|||
Target ID: CHEMBL217 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | VESPRIN Approved UseUsed mainly in the management of psychoses. Also used to control nausea and vomiting Launch Date-3.87935994E11 |
Doses
Dose | Population | Adverse events |
---|---|---|
800 mg 1 times / day multiple, oral Overdose Dose: 800 mg, 1 times / day Route: oral Route: multiple Dose: 800 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Psychotic disorders Sources: |
|
150 mg 1 times / day multiple, intramuscular Recommended Dose: 150 mg, 1 times / day Route: intramuscular Route: multiple Dose: 150 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Psychotic disorders Sources: |
|
3 mg 1 times / day multiple, intravenous Recommended Dose: 3 mg, 1 times / day Route: intravenous Route: multiple Dose: 3 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Nausea Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Aluminum balance in intensive care patients. | 2001 Apr |
|
[Prophylaxis of nausea and vomiting after thyroid surgery: comparison of oral and intravenous dolasetron with intravenous droperidol and placebo]. | 2001 Jul |
|
Inactivation of cholinesterase induced by chlorpromazine cation radicals. | 2003 Feb |
|
A kinetic study on the phenothiazine dependent oxidation of NADH by bovine ceruloplasmin. | 2006 Feb |
|
Effects of inorganic ions on the binding of triflupromazine and chlorpromazine to bovine serum albumin studied by spectrometric methods. | 2006 Jul |
|
Synthesis and antitubercular activity of quaternized promazine and promethazine derivatives. | 2007 Mar 1 |
|
The effect of calmodulin antagonists on experimental scoliosis: a pinealectomized chicken model. | 2009 Mar 15 |
|
Effects of chemical manipulation of mitotic arrest and slippage on cancer cell survival and proliferation. | 2009 Sep 15 |
|
A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle. | 2010 Feb 23 |
|
Research on antipsychotics in India. | 2010 Jan |
|
The identification of inhibitors of Schistosoma mansoni miracidial transformation by incorporating a medium-throughput small-molecule screen. | 2010 Jun |
|
Changes in clinical trials methodology over time: a systematic review of six decades of research in psychopharmacology. | 2010 Mar 3 |
Patents
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 520.2582
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
||
|
WHO-ATC |
N05AA05
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
||
|
WHO-VATC |
QN05AA05
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
||
|
NCI_THESAURUS |
C740
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
||
|
NCI_THESAURUS |
C29710
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
4330
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
PRIMARY | |||
|
10805
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
PRIMARY | RxNorm | ||
|
2742
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
PRIMARY | |||
|
TRIFLUPROMAZINE
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
PRIMARY | |||
|
725
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
PRIMARY | |||
|
C66635
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
PRIMARY | |||
|
3407
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
PRIMARY | |||
|
m11123
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
PRIMARY | Merck Index | ||
|
205-673-6
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
PRIMARY | |||
|
DTXSID9023704
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
PRIMARY | |||
|
CHEMBL570
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
PRIMARY | |||
|
146-54-3
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
PRIMARY | |||
|
SUB11290MIG
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
PRIMARY | |||
|
9711
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
PRIMARY | |||
|
D014273
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
PRIMARY | |||
|
5568
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
PRIMARY | |||
|
RO16TQF95Y
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
PRIMARY | |||
|
DB00508
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
PRIMARY | |||
|
100000088513
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)